Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Macrocyclic kinase inhibitors and uses thereof
Dana-farber Cancer Institute, Inc.
July 20, 2017 - N°20170204116

The present disclosure provides macrocyclic compounds of formula (i). The provided compounds are able to bind protein kinases and may be useful in modulating (e. G., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e. G., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, ...
Therapeutic isoxazole compounds
Dana-farber Cancer Institute, Inc.
July 20, 2017 - N°20170204111

Wherein a1, a2, a3, r1, x, y, and b have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase b (mao-b) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders ...
Imidazolyl kinase inhibitors and uses thereof
Dana-farber Cancer Institute, Inc.
July 20, 2017 - N°20170204082

The present disclosure provides imidazolyl compounds of formula (i) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e. G., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e. G., proliferative disease, genetic disease, hematological disease, ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof
Universitat Bern
July 13, 2017 - N°20170197936

The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions. These applications for manufacture of the ...
Allosteric modulators of cb1 cannabinoid receptors
Northeastern University
July 13, 2017 - N°20170197918

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of ...
2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and ...
Northeastern University
July 06, 2017 - N°20170190678

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
July 06, 2017 - N°20170189358

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e. G., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic ...
6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
June 29, 2017 - N°20170183342

The present invention is directed to 6,7-dihydro-5h-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the m4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which m4 muscarinic acetylcholine receptors are involved. The present invention is ...
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
Merck Patentgesellschaft
June 29, 2017 - N°20170182011

Their use as allosteric modulators of mglur5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
June 29, 2017 - N°20170181989

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e. G., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic ...
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
June 29, 2017 - N°20170181983

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-r-mecamylamine, said ...
Compositions and methods for treating neurodegenerative diseases
Azevan Pharmaceuticals, Inc.
June 22, 2017 - N°20170174670

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as huntington's disease, parkinson's disease, and alzheimer's disease.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted imidazo[1,5-a]pyrazines as pde9 inhibitors
Allergan, Inc.
June 22, 2017 - N°20170173018

The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (i). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of ...
Methods for diagnosing and treating neuroimmune-based psychiatric disorders
The Regents Of The University Of California
June 15, 2017 - N°20170166968

The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biological sample. The methods of the present invention are also useful for the in vivo imaging of brain tissue by detecting one or ...
Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
Takeda Pharmaceutical Company Limited
June 15, 2017 - N°20170166553

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-i
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158628

The present invention relates to chemical compounds of formula (i), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nachr). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ...
Anti-depression compounds
Board Of Regents Of The University Of Texas System
June 08, 2017 - N°20170157092

This technology relates generally to compounds and methods for stimulating neurogenesis (e. G., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal ...
Mecp2e1 gene
Centre For Addiction And Metal Health
June 01, 2017 - N°20170152564

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Substituted pyrazino[2,2-a]isoquinoline derivatives
Centre For Addiction And Metal Health
May 25, 2017 - N°20170145010

The present invention relates to compounds of formula of formula i wherein r, r2and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
Substituted azetidine derivatives
Centre For Addiction And Metal Health
May 25, 2017 - N°20170144994

The present invention relates to compounds of formula of formula i wherein r, r1. R2, r2′, r3, r4, r5, l1, l2 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
Loading